Author: GSBS | Category: In The News | Biomedical Engineering (M.S.) | Biomedical Engineering (Ph.D.) | June 26, 2017
UT Health San Antonio and UT Health Houston announced a landmark agreement Friday to grant exclusive global licenses for two biologic therapeutics to AlaMab Therapeutics Inc., a subsidiary of CSPC Pharmaceutical Group, in a deal that could be worth up to $114 million. Fun Fact: That's our graduate student Daniel Shropshire in the photo!
Copyright © 2019 The University of Texas Health Science Center at San Antonio
Links provided from the UTHSCSA pages to other websites do not constitute or imply an endorsement of those sites, their content, or products and services associated with those sites.